Produkty
Producenci
Synercid
Opis
Produkt przeznaczony wyłącznie do badań. Nie nadaje się do spożycia. Więcej informacji na stronie producenta www.toku-e.com
Synercid is a combination of 30 parts Quinupristin and 70 parts Dalfopristin, which are considered semisynthetic streptogramin antibiotics (macromolecular antibiotics produced by Streptomyces pristinaepiralis) and together, the compounds act synergistically as each is bacteriostatic, but Synercid is bactericidal. Synercid also inhibits the isoenzyme cytochrome P450-3A4. Synercid is derived from Pristinamycin (Quinupristin is derived from pristinamycin IA; dalfopristin from pristinamycin IIA). The compound was developed 1989 by the Rhône-Poulenc company in France. The product is soluble in water.
Cas Number: 126602-89-9
Molecular Formula: C87H117N13O19S2
Molecular Weight: 1713.07
Mechanism of Action: Synercid acts as a synergistic protein synthesis inhibitor at different stages of ribosomal translation. Dalfopristin targets the early stages of protein synthesis by binding to the 23S portion of the 50S ribosomal subunit inhibiting peptidyl transferase, the enzyme involved in peptide bond formation. Quinupristin targets later stages of protein synthesis by binding to the 50S subunit near Dalfopristin, preventing polypeptide elongation and release. The synergistic effect is explained by the conformational change in the ribosome caused by Dalfopristin which allows Quinupristin to bind to the ribosome with higher affinity. Synercid inhibits the isoenzyme cytochrome P450-3A4.
Storage Conditions: 2-8 °C
Application
Spectrum: Synercid is active against a range of Gram-positive bacteria including meticillin- and multidrug-resistant strains of Staphylococcus aureus and S. epidermidis, vancomycin-resistant Enterococcus faecium (but not E. faecalis), and penicillin- and macrolide-resistant Streptococcus pneumoniae. It is also active against the anaerobe Clostridium perfringens, and Gram-negative bacteria Legionella pneumophila, Moraxella catarrhalis (Branhamella catarrhalis), and Neisseria meningitidis. It is also active against Mycoplasma spp. including M. pneumoniae.
Microbiology Applications: Synercid is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include: Enterococcus faecium: 0.5 µg/mL- 4 µg/mL Streptococcus pyogenes: 0.06 µg/mL- 2 µg/mL For a representative list of Synercid MIC values, click here. Editor note: Add link: http://antibiotics.toku-e.com/antimicrobial_1000.html An in vitro susceptibility test study with more than 28,000 clinical isolates from 200 centers across North America found Synercid to be consistently active (≥90% susceptible) against major Gram-positive pathogens. It had an MIC of ≤1 µg per ml in 90% of strains in a wide variety of multidrug-resistant Gram-positive bacteria including E. faecium, MRSA, and S. epidermidis (Jones et al, 1998).
Form: Powder
Appearance: white to light yellow powder
Source: Semi-synthetic
Solubility: soluble in water
Purity Level: ≥95% (by HPLC)
References: Allington DR and Rivey MP (2001) Quinupristin/dalfopristin: A therapeutic review. Clin. Ther. 23:24 Chant C et al (1995) Quinupristin/dalfopristin (RP 59500): A new streptogramin antibiotic. Ann. Pharm. 29:1022 Delgado G., Neuhauser MM. Bearden DT, and Danziger LH (2000). Quinupristin-dalfopristin: An overview. Pharmacother. 20:1469–1485 Folcher M et al (2001). A transcriptional regulator of a Pristinamycin resistance gene in Streptomyces coelicolor. J. Biol. Chem. 276(2): 1479-1485 Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, and Schentag JJ. (1998) Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn. Microbiol. Infect. Dis. 31:437–451 PMID 9635235 Manzella JP (2001) Quinupristin-dalfopristin: A new antibiotic for severe gram-positive infections. Am. Fam. Physician 64(11):1863-1866 PMID 11764864
Dane techniczne
| Opakowanie | 10 mg |